1. Home
  2. KREF vs ALT Comparison

KREF vs ALT Comparison

Compare KREF & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KKR Real Estate Finance Trust Inc.

KREF

KKR Real Estate Finance Trust Inc.

HOLD

Current Price

$6.70

Market Cap

399.8M

Sector

Real Estate

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.40

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KREF
ALT
Founded
2014
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
399.8M
421.5M
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
KREF
ALT
Price
$6.70
$3.40
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$9.58
$17.67
AVG Volume (30 Days)
1.3M
2.6M
Earning Date
04-22-2026
05-12-2026
Dividend Yield
15.18%
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
$545.92
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$5.87
$2.87
52 Week High
$9.98
$7.73

Technical Indicators

Market Signals
Indicator
KREF
ALT
Relative Strength Index (RSI) 56.40 46.77
Support Level $6.64 $2.87
Resistance Level $7.50 $4.25
Average True Range (ATR) 0.19 0.16
MACD 0.09 0.06
Stochastic Oscillator 99.40 76.87

Price Performance

Historical Comparison
KREF
ALT

About KREF KKR Real Estate Finance Trust Inc.

KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: